Alberto Daniele1, A Ferrero2, L Fuso2, M Mineccia3, V Porcellana4, D Vassallo5, N Biglia2, G Menato2. 1. Academic Division of Gynecology and Obstetrics, Mauriziano Hospital, Via Magellano,1, 10128, Turin, Italy. albertodaniele@hotmail.it. 2. Academic Division of Gynecology and Obstetrics, Mauriziano Hospital, Via Magellano,1, 10128, Turin, Italy. 3. Department of Surgery, Mauriziano Hospital, Via Magellano,1, 10128, Turin, Italy. 4. Service of Palliative Care, Mauriziano Hospital, Via Magellano,1, 10128, Turin, Italy. 5. Service of Dietetics, Mauriziano Hospital, Via Magellano,1, 10128, Turin, Italy.
Abstract
OBJECTIVE: Malignant bowel obstruction (MBO) is usually a pre-terminal event in patients with ovarian cancer. However, because of the lack of data in literature, decisions around surgical intervention, non-resectional procedures, or medical treatment of MBO in patients with ovarian cancer cannot be lightly undertaken. We analyzed medical and surgical procedures, performance status, nutritional status, cachexia, and their prognostic value in this group of patients. METHODS: We retrospectively selected all consecutive patients with recurrent ovarian cancer who received medical or surgical treatment for MBO between October 2008 and January 2014 at the Academic Department of Gynecological Oncology of Mauriziano Hospital of Turin (Italy). RESULTS: We found 40 patients: 18 of them underwent medical treatment and 22 of them were submitted to surgery. In the group of surgery, the hospitalization was shorter (p 0.02), the pain reduction was more effective (p 0.001), the number of chemotherapy lines was higher (p 0.03), and re-obstruction was more rare (p 0.02). Between the two groups, we did not find any differences in post-palliation episodes of vomit (p 0.83), type of diet (p 0.34), ability to return home (p 0.72), and death setting (p 0.28). Median survival after palliation was longer in the group of surgery (p 0.025). Cachexia, low performance status, and poor nutritional status were significant predictors of worse survival after MBO, independently by the treatment. CONCLUSIONS: Surgery has to be considered in patients without serious contraindications; otherwise, a medical protocol, including antisecretory drugs, is the standard of care in frail patients.
OBJECTIVE:Malignant bowel obstruction (MBO) is usually a pre-terminal event in patients with ovarian cancer. However, because of the lack of data in literature, decisions around surgical intervention, non-resectional procedures, or medical treatment of MBO in patients with ovarian cancer cannot be lightly undertaken. We analyzed medical and surgical procedures, performance status, nutritional status, cachexia, and their prognostic value in this group of patients. METHODS: We retrospectively selected all consecutive patients with recurrent ovarian cancer who received medical or surgical treatment for MBO between October 2008 and January 2014 at the Academic Department of Gynecological Oncology of Mauriziano Hospital of Turin (Italy). RESULTS: We found 40 patients: 18 of them underwent medical treatment and 22 of them were submitted to surgery. In the group of surgery, the hospitalization was shorter (p 0.02), the pain reduction was more effective (p 0.001), the number of chemotherapy lines was higher (p 0.03), and re-obstruction was more rare (p 0.02). Between the two groups, we did not find any differences in post-palliation episodes of vomit (p 0.83), type of diet (p 0.34), ability to return home (p 0.72), and death setting (p 0.28). Median survival after palliation was longer in the group of surgery (p 0.025). Cachexia, low performance status, and poor nutritional status were significant predictors of worse survival after MBO, independently by the treatment. CONCLUSIONS: Surgery has to be considered in patients without serious contraindications; otherwise, a medical protocol, including antisecretory drugs, is the standard of care in frail patients.
Entities:
Keywords:
Malignant bowel obstruction; Ovarian cancer; Palliative care
Authors: G Mangili; G Aletti; L Frigerio; M Franchi; N Panacci; R Viganò; P DE Marzi; F Zanetto; A Ferrari Journal: Int J Gynecol Cancer Date: 2005 Sep-Oct Impact factor: 3.437
Authors: Jon C Henry; Severin Pouly; Rachael Sullivan; Suhail Sharif; Dori Klemanski; Sherif Abdel-Misih; Nicole Arradaza; David Jarjoura; Carl Schmidt; Mark Bloomston Journal: Surgery Date: 2012-08-26 Impact factor: 3.982
Authors: Anne Marie Sowerbutts; Simon Lal; Jana Sremanakova; Andrew Clamp; Chris Todd; Gordon C Jayson; Antje Teubner; Anne-Marie Raftery; Eileen J Sutton; Lisa Hardy; Sorrel Burden Journal: Cochrane Database Syst Rev Date: 2018-08-10
Authors: Yeh Chen Lee; Nazlin Jivraj; Catherine O'Brien; Tanya Chawla; Eran Shlomovitz; Sarah Buchanan; Jenny Lau; Jennifer Croke; Johane P Allard; Preeti Dhar; Stephane Laframboise; Sarah E Ferguson; Neesha Dhani; Marcus Butler; Pamela Ng; Terri Stuart-McEwan; Pamela Savage; Lisa Tinker; Amit M Oza; Stephanie Lheureux Journal: Obstet Gynecol Int Date: 2018-05-17